Pα+ Psychedelic Bulletin #187: NYT Article Reignites MDMA Rejection Blame Game; FDA “Wanted to Approve” MDMA, MindMed Exec Says; GH’s Data and RFK Jr. Confirmation Send Psychedelics Stocks Soaring
- The Psychedelic Blame Game: NYT Report Fuels Controversy Over MDMA Rejection
- The Authors
- Mixed Messages on Psymposia’s Role
- Lykos and MAPS Seize the Opportunity
- Political Pragmatism Sparks Backlash Among Some Supporters
- Devenot and Doblin Respond
- Psychedelic Drug Developers Reflect on “Lykos-Specific Issues” and the Road Ahead
- FDA “Wanted to Approve” MDMA, Says MindMed Exec
- Trump on Psychedelics; “Nothing” Lies Beyond Psychological Support; Trial Site Availability Limits Psychedelic Drug Development
- GH’s 5-MeO-DMT Data and RFK Jr. Confirmation Send Psychedelics Stocks Soaring
- Other Stories
The Psychedelic Blame Game: NYT Report Fuels Controversy Over MDMA Rejection
Earlier this week, The New York Times published a story that, above all, suggests that Psymposia was substantially to blame for FDA’s August rejection of Lykos Therapeutics’ MDMA-assisted therapy for PTSD new drug application (NDA), and that “other psychedelic drugs in the pipeline could be jeopardized.” Murmurs of the reporting had been swirling for some time and its publication has been met with excitement by many in the field...
Join Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
- Regular Bulletins featuring news, analysis, and research
- Articles and deep dives across psychedelic drug development, policy, and research
- Exclusive interviews with researchers, executives, and policymakers
- Bespoke resources and tools including the Psychedelic Bill Tracker
- Quarterly video briefings and slide decks
Already a member?
Sign In